Stakeholders | Open-ended questions |
---|---|
a) The commercial and for-profit sector b) Policymakers c) Academic professor in faculty of pharmacy d) WHO consultant | • Existence of a national medicines regulatory agency (NMRA) responsible for the promulgation and enforcement of regulations. • Existence of a system for pharmaceutical registration. • Existence of a pharmacovigilance system. • Mechanisms exist for licensing, inspection, and quality control. • Views about different pricing policies. • Production and trade. |
Pharmacists | • Knowledge about the essential drug list (EDL). • Existence of functioning mechanisms to improve dispensing practices. • Existence of drug committee and what is its function. • Opinion about the quality of generic versus brand. • Percent of prescribed medicines from EDL. • Percent of medicines prescribed by generic name. • The percent availability and the average period of stock-outs of unexpired essential tracer medicines. |
Physicians | • Prescribing behavior of physicians • Perception of affordability • Attitudes of physicians toward generic drugs prescribing • Relation to medical representatives • Perception of EDL policies • Perception and commitment to guidelines’ policies • Perception and suggestions about pharmaceutical management |